Developing new tools to identify and target proteins shed by cancer cells
New protein-engineered tools and technologies for identifying, deorphanizing, and targeting shed proteins in cancer
This study is looking at how cancer cells release certain proteins that can change how they act and interact, and it aims to find new ways to target these proteins to help create better treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11133363 on NIH RePORTER |
What this research studies
This research focuses on understanding how cancer cells shed proteins that can influence their behavior and interactions. By using advanced mass spectrometry techniques, the team aims to identify these shed proteins and their roles in cancer progression. The project will also develop new antibody tools that can specifically target these proteins, potentially leading to innovative treatments. Patients may benefit from insights into how these proteins affect cancer and from new therapeutic options that arise from this research.
Who could benefit from this research
Good fit: Ideal candidates for this research include cancer patients who may have elevated levels of shed proteins affecting their disease.
Not a fit: Patients with non-cancerous conditions or those whose cancer does not involve shed proteins may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for cancer patients by identifying and blocking harmful shed proteins.
How similar studies have performed: Other research has shown promise in targeting shed proteins in cancer, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Wells, James a — University of California, San Francisco
- Study coordinator: Wells, James a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.